Press Releases May 5, 2026 01:39 PM

Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026

Mesa Laboratories to Release Q4 and Full Fiscal Year 2026 Financial Results on May 27

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
MLAB

Mesa Laboratories, Inc., a Nasdaq-listed company specializing in life science tools and quality control solutions for regulated industries, announced it will report its fourth quarter and full fiscal year 2026 financial results on May 27, 2026.

Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
MLAB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Announcement of upcoming financial results for Q4 and full fiscal year ending March 31, 2026.
  • Mesa Laboratories is a global leader in life science tools and critical quality control for pharmaceuticals, healthcare, and medical devices.
  • The company's products aim to enhance product integrity, patient and worker safety, and overall quality of life.

LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026.

About Mesa Laboratories
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

Mesa Laboratories Contacts
Siddhartha Kadia, President and CEO
John Sakys, Vice President and CFO
1-303-987-8000

For more information about Mesa Laboratories, please visit our website at www.mesalabs.com.


Risks

  • Financial results may fall short of market expectations, impacting stock performance.
  • Regulatory changes in pharmaceutical and healthcare industries could affect demand for Mesa's products.
  • Market competition and technological advancements may pose challenges to Mesa's market position.

More from Press Releases

Retension Pharmaceuticals Announces Pricing of Initial Public Offering Oct 8, 2026 TRexBio Announces Pricing of Initial Public Offering Oct 8, 2026 Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027 Oct 8, 2026 Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet Oct 8, 2026 Bitdeer AI Expands Southeast Asia Footprint with A901, a New 67MW AI Data Center Campus in Malaysia; Active AI Cloud Pipeline Exceeds $10 Billion Oct 8, 2026